Literature DB >> 6349780

Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report.

G A Higgins, J H Amadeo, D E Smith, E W Humphrey, R J Keehn.   

Abstract

This prospective evaluation of 5-fluorouracil (5-FU) and methyl-CCNU administered in combination to patients with surgery for histologically proved gastric adenocarcinoma is based upon 312 patients randomized between August 1974 and May 1980. Patients were stratified into three categories of resectability, (1) complete, (2) proven incomplete, and (3) nonresectable, prior to random treatment assignment to surgery alone or surgery followed by adjuvant chemotherapy. Drug therapy consisted of discrete 5-day courses administered at 7-week intervals. Toxic reactions were reported in association with 42% of the courses. Treatment was suspended or discontinued in 6% of the courses because of hematologic toxicity. Treated patients with curative resections experienced a more favorable survival than did controls, but the early advantage was lost by the end of the second follow-up year. However, no statistically significant improvements in survival or reductions in risks of recurrence were observed. Similar proportions of treated and control deaths were attributable to residual or recurrent disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6349780     DOI: 10.1002/1097-0142(19830915)52:6<1105::aid-cncr2820520629>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Kyoto Research Group for Digestive Organ Surgery.

Authors: 
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

2.  Adjuvant chemotherapy in gastric cancer.

Authors:  P Schlag
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

Review 3.  Diagnosis and treatment of gastric cancer.

Authors:  A Hendlisz; H Bleiberg
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

4.  Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials.

Authors:  Jian-Kun Hu; Zhi-Xin Chen; Zong-Guang Zhou; Bo Zhang; Jing Tian; Jia-Ping Chen; Li Wang; Chao-Hua Wang; Hong-Yan Chen; You-Ping Li
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

5.  Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors.

Authors:  Chiara Carlomagno; Elide Matano; Roberto Bianco; Carolina Cimminiello; Antonella Prudente; Clorindo Pagliarulo; Anna Crispo; Lucia Cannella; Alfonso DE Stefano; Francesco Paolo D'Armiento; Sabino DE Placido
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

Review 6.  Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy.

Authors:  J A Ajani; P F Mansfield; D M Ota
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 7.  Adjuvant treatment of gastric cancer.

Authors:  J S Macdonald; S F Schnall
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 8.  Chemotherapy for patients with gastric cancer after complete resection: a network meta-analysis.

Authors:  Ya-Wu Zhang; Yu-Long Zhang; Hui Pan; Feng-Xian Wei; You-Cheng Zhang; Yuan Shao; Wei Han; Hai-Peng Liu; Zhe-Yuan Wang; Sun-Hu Yang
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

9.  Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up.

Authors:  J Estape; J J Grau; F Lcobendas; J Curto; M Daniels; N Viñolas; C Pera
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

10.  Gastric carcinoma in China: Current status and future perspectives (Review).

Authors:  Xiaodong Zhu; Jin Li
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.